A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Sponsor: Karyopharm Therapeutics Inc
Terminated
Upon further consideration of the existing data and the competitive landscape, Karyopharm Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this time.
Other terminated trials from Karyopharm Therapeutics Inc
- Post-essential Thrombocythemia Myelofibrosis · Phase PHASE2 · Mar 2025
- Advanced Urothelial Carcinoma · Phase PHASE1/PHASE2 · Feb 2024
- Locally Advanced Unresectable or Metastatic Melanoma · Phase PHASE2 · Sep 2023
- Non-small Cell Lung Cancer · Phase PHASE1/PHASE2 · Mar 2023
- Myeloma · Phase PHASE2 · Dec 2022
More terminations from Karyopharm Therapeutics Inc
Other Glioblastoma Multiforme trials with similar outcome
Listed as NCT04421378, this PHASE1/PHASE2 trial focuses on Glioblastoma Multiforme and remains terminated or withdrawn. Sponsored by Karyopharm Therapeutics Inc, it has been updated 17 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Jan 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Aug 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 12 earlier versions
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2022 — Jan 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Karyopharm Therapeutics Inc
For direct contact, visit the study record on ClinicalTrials.gov .